肝癌监测高危患者:专家观点
本文为专家观点,指出肝癌监测基于观察性研究,缺乏随机试验证据,国家筛查委员会等机构支持有限;筛查在低患病率人群中进行且检测不完美,多数阳性为假阳性;基于风险的监测或可改善结局,需更强证据与倡导。
要点
- 肝癌监测缺乏随机试验证据,超出肝病领域的组织支持有限。
- 筛查多在低患病率人群中进行,检测不完美,多数阳性结果为假阳性。
- 基于风险的肝细胞癌监测可能通过个体化风险分层改善结局。
核心结论
- 肝癌监测有强 rationale 和观察性研究支持,但缺乏随机试验证据,限制国家筛查委员会等组织支持。
- 基于风险的肝细胞癌监测可能通过个体化风险分层改善结局,但证据基础薄弱。
研究设计与样本
- 专家观点文章,未报告系统检索或样本量。
主要发现
- 筛查常在低患病率人群中进行,检测不完美,多数阳性结果为假阳性。
- 许多患者因癌症发病率低、检测敏感性有限和竞争性死亡风险而未获显著获益。
- 已有许多风险预测模型,并已在慢性乙型肝炎患者中实施。
临床怎么用
- 可考虑基于风险的肝细胞癌监测,依据个体风险特征调整监测策略。
- 需更强证据、持续倡导及与国家/国际筛查委员会沟通以改善监测实践。
局限性
- 缺乏随机试验证据,证据基础薄弱。
- 筛查检测不完美,低患病率人群中假阳性率高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Liver cancer surveillance is supported by a strong rationale and observational research; however, evidence from randomised trials is lacking, limiting support from organisations beyond hepatology, such as national screening committees. The absence of such trials has been acknowledged in the hepatology community for over 25 years. Screening is often performed in low-prevalence populations, and screening tests are imperfect. As a result, most positive results are false positives. Although novel screening modalities are being investigated to complement or replace ultrasound for liver cancer surveillance, challenges remain, particularly regarding the weak evidence base. The ultimate aim of liver cancer surveillance is to improve survival, but many patients do not experience notable benefits due to low cancer incidence, limited test sensitivity, and competing mortality risks. Implementing risk-based hepatocellular carcinoma surveillance, as recommended by some guidelines, may enhance outcomes by tailoring surveillance to individual patient risk profiles. Many risk prediction models exist, and they have been implemented for patients with chronic hepatitis B. Stronger evidence, persistent advocacy, and consultations with national and international screening committees could pave the way for improved liver cancer surveillance practices.
引用
- Yip TC, Innes H, Wong GL, et al. Surveillance of patients at risk of liver cancer: Expert opinions. J Hepatol. 2026. PMID: 42436054. doi:10.1016/j.jhep.2026.03.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。